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ABSTRACT
The replication protein A (RPA)–ssDNA complex
formed at arrested replication forks recruits key
proteins to activate the ATR-CHK1 signalling cas-
cade. When CHK1 is inhibited during DNA replica-
tion stress, RPA2 is extensively hyperphosphory-
lated. Here, we investigated the role of RPA2 hyper-
phosphorylation in the fate of cells when CHK1 is
inhibited. We show that proteins normally involved
in DNA repair (RAD51) or control of RPA phospho-
rylation (the PP4 protein phosphatase complex) are
not recruited to the genome after treatment with
CHK1 and DNA synthesis inhibitors. This is not
due to RPA2 hyperphosphorylation as suppression
of this response does not restore loading suggest-
ing that recruitment requires active CHK1. To deter-
mine whether RPA2 hyperphosphorylation protects
stalled forks from collapse or induction of apopto-
sis in CHK1 inhibited cells during replication stress,
cells expressing RPA2 genes mutated at key phos-
phorylation sites were characterized. Mutant RPA2
rescued cells from RPA2 depletion and reduced the
level of apoptosis induced by treatment with CHK1
and replication inhibitors however the incidence of
double strand breaks was not affected. Our data indi-
cate that RPA2 hyperphosphorylation promotes cell
death during replication stress when CHK1 function
is compromised but does not appear to be essential
for replication fork integrity.
INTRODUCTION
DNAdamage response pathways preserve genome integrity
by recognizing replication errors and DNA damage to ar-
rest cell cycle progression and activate repair. These path-
ways may also commit highly damaged cells to death. Work
from a many laboratories has identified CHK1 as a key me-
diator of cell death following DNA replication inhibition or
some forms of DNA damage (1–3). DNA replication stress
triggers apoptosis in the absence of CHK1 function, par-
ticularly in tumour cells where oncogene activation may in-
appropriately drive DNA replication (4,5). This has led to
renewed interest in the use of CHK1 inhibitors in therapies
targeted to tumour cells (6–9). CHK1 is largely activated
as a result of ssDNA formation that may be generated by
the uncoupling of polymerase and helicase complexes fol-
lowing DNA replication inhibition (10) or by other path-
ways that process stalled replication forks (11). Replication
protein A (RPA) rapidly coats ssDNA to form an RPA-
ssDNA complex that recruits Ataxia telangiectasia mutated
and Rad3 related (ATR) through a complex mechanism in-
volving the ATR interacting protein (ATRIP) (12,13). ATR
then activates CHK1 through phosphorylation of Ser345
and Ser317 (14,15) to coordinate cellular responses to repli-
cation stress. It slows S-phase progression by suppressing in-
appropriate firing of replication origins, helpsmaintain fork
integrity, facilitates resolution of stalled forks, and triggers
G2/M arrest (16–19).
RPA plays a wide role in DNA metabolism (20,21). It
coats ssDNA to protect it from nucleolytic attack and re-
move secondary structure and interacts with a number of
proteins during replication or repair. RPA is a heterotrimer
consisting of 70, 32 and 14 kDa subunits. The 70 and 32 kDa
subunits containDNAbindingmotifs necessary for recruit-
ment of the complex to ssDNA (22) while the 32 kDa sub-
unit (RPA2) is the target of phosphorylation during normal
G1/S transition at conserved cyclin-CDK phosphorylation
sites (Ser23 and Ser29) (23,24). When DNA is damaged or
replication is disrupted under some conditions other sites
on RPA2 may be phosphorylated by PIK-like kinases in-
cluding DNA-PK, ATM and ATR to produce a ‘hyper-
phosphorylated’ state (23–28). The role of hyperphospho-
rylated RPA2 in the response to replication fork stress has
been extensively studied. The sites are not essential for RPA
function in unstressed cells as nonphosphorylatable mutant
RPA2 has no effect on normal cell growth (29,30) although
initial reports suggested that RPA2 phosphorylation may
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enhance or inhibit replication or repair (30–33). More re-
cent findings indicate that it mediates S-phase checkpoints
and recovery from replication stress (28,33,34). In particu-
lar phosphorylation of Ser4/Ser8 by DNA-PK appears to
be required for induction of S-phase checkpoints and reg-
ulation of replication fork restart after exposure to repli-
cation inhibitors (28,34,35). While RPA levels have been
shown to be critical to prevent replication fork collapse fol-
lowing treatment with an ATR inhibitor (36), the role of
RPA2 hyperphosphorylation is not known.
We previously showed that RPA2 hyperphosphorylation
is enhanced in CHK1 depleted cells exposed to replication
inhibitors relative to cells treated with replication inhibitors
alone (37). Considering the potential impact of this protein
modification on high levels of ssDNA generated at arrested
DNA replication forks in tumour cells under these condi-
tions (38,39), we investigated the relationship of RPA2 hy-
perphosphorylation to cell fate.
MATERIALS AND METHODS
Cell culture
The HCT116 and SW480 human colon cancer cell lines
were obtained from American Type Culture Collection
(Manassas, VA, USA). Cells were maintained in DMEM
supplemented with 10% fetal bovine serum (FBS). For ex-
periments using thymidine, dialyzed FBS was used to re-
move deoxynucleosides in the serum that might interfere in
the response to this agent. Replication inhibitors thymidine
(TdR) and hydroxyurea (HU) were used at a concentration
2 mM although 4 mM thymidine was used for SW480. The
chemical inhibitor of Chk1 activity (Go¨6976, Calbiochem
(40) or MK-8776, Selleckchem (41)) was added to cell cul-
tures at a concentration of 1 M 1h prior treatment with
replication inhibitors. Stable transfected HCT116 cells were
growing in DMEM supplemented with 10% FBS and 2
g/ml puromycin.
RPA2 mutagenesis and plasmid transfection
RPA2 cDNA cloned into pOTB7RPA2 plasmid (IMAGE
clone: 3538351, BC001630.1, Gene Service Ltd) was ampli-
fied and subcloned into pcDNA3.1/V5-His TOPO vector
(Invitrogen, Life Technologies). The RPA2 serine to alanine
mutations at amino acids 4, 8, 33, 29 and 23 were generated
by four consecutive site-directedmutagenesis reactions. The
primer sequences used were:
Ser33Ala forward 5′GCCACCATGTGGAACGGTGG
ATTCGAAGGCTATGGC
5′GGCTTTGGATCGCCCGCACCTgCTCAAGCC
GAAAAGAAATCAAGA, Ser33Ala reverse 5′TCTTGA
TTTCTTTTCGGCTTGAGcAGGTGCGGGCGATC
CAAAGCC,
Ser29Ala forward 5′CAGTCCCCGGGGGGCTTTG
GAgCGCCCGCACCTTCTCAAGCCGAA, Ser29Ala r
everse 5′TTCGGCTTGAGAAGGTGCGGGCGcTCC
AAAGCCCCCCGGGGACTG, Ser23Ala forward 5′G
GAGCCGGCGGCTACACGCAGgCCCCGGGGGGC
TTTGGATCGCCC, Ser23Ala reverse 5′GGGCGATCC
AAAGCCCCCCGGGGcCTGCGTGTAGCCGCCGG
CTCC.
Ser4,8Ala forward 5′GCCACCATGTGGAACgGTGG
ATTCGAAgGCTATGGC, Ser4,8Ala reverse 5′GCTAGC
GACGTCGGCGCGCCCTCGAGTCGC.
The RPA2 wild type and mutant were subcloned into
pCAG-Flox and HCT116 were stably transfected using
Lipofectamine 2000 (Invitrogen, Life Technologies) in ac-
cording to manufacturer’s instructions. The cells that inte-
grated the gene were selected using 2 g/ml puromycin.
siRNA transfection
For CDC45 depletion a set of siRNAs were used (ON-
TARGETplus CDC45 siRNA, L-003232, Dharmacon, GE
Healthcare). For endogenous RPA2 depletion a pool of
three different siRNAs targeted to 3′ untranslated gene
region were used (ON-TARGETplus siRNA J-017058-09,
J-017058-11, J-017058-12, Dharmacon, GE Healthcare).
The corresponding sense sequences are AACAUGAAGU-
UCUGCGGUA, GAGCAGGACCAGGGCGUUA and
GGAAGUAGGUUUCAUCUAU. Control siRNAs, con-
taining nonspecific sequences that do not have homology
in human genome, were provided by Eurofins (UAAU-
GUAUUGGAACGCAUA). siRNA duplexes were trans-
fected into cells using Lipofectamine 2000 (Invitrogen,
Life Technologies) according to manufacturer’s instruc-
tions. The cells were then incubated for 24 h before further
treatment.
Cell cycle and caspase3 analysis
Cells were collected after the treatment, fixed with 70% ice-
cold ethanol and stored at −20◦C. After fixation, cells were
washed twice with PBS and incubated for 15 min in PBS-
T (PBS, 0.1% BSA, 0.25% Triton X-100). After centrifuga-
tion, the cell pellet was suspended in the same buffer plus an
antibody specifically recognizing cleaved-caspase3 (Cleaved
Caspase-3 (Asp175)Antibody 9661, Cell Signalling) diluted
1:500 and incubated for 3 h at room temperature. The cells
were then rinsed with PBS containing 0.25% Triton X-100
and incubated with the FITC-conjugated goat anti-rabbit
immunoglobulins antibody (sc-2012, Santa Cruz Biotech-
nology) diluted at a ratio of 1:30 in PBS containing 1%BSA.
After a 30 min incubation at room temperature in the dark,
the cells were washed with PBS and stained with PI solution
(PBS with 5 g/ml PI and 100 g/ml RNAse A), and cel-
lular fluorescence was measured by flow cytometry (LSRII,
BectonDickinson,Oxford,UK) and analysed using FlowJo
software.
Immunofluorescence
HCT116 cells were cultured on glass coverslips and treated
as indicated. Cells were then fixed with 3% buffered
paraformaldehyde for 15 min at RT, incubated in PBS
containing 30 mM NH4Cl for 5 min and permeabilized
in PBS containing 0.5% Triton X-100 for 8 min at RT.
Cells were stained using an anti-phosphoRPA2 Ser-4,8
(A300-245A) from Bethyl cells diluted 1:1000 for 45 min
at RT and detected with Alexa 488-conjugated goat anti-
rabbit IgG (A11008; Molecular Probes, Invitrogen) diluted
1:1000. Antibody dilutions and washes after incubations
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were performed in PBS containing 0.5% BSA and 0.05%
Tween 20. Coverslips were finally mounted in Vectashield
mounting medium with DAPI (H-1500; Vector Laborato-
ries, Burlingame, CA, USA). Resulting fluorescence was vi-
sualized using a Nikon Eclipse T200 microscope equipped
with a Hamamatsu Orca ER camera and the Volocity 3.6.1
(Improvision, Cambridge, UK) software. Pictures were fur-
ther processed using Image J software (http://rsbweb.nih.
gov/ij/).
Protein extraction and Western blotting
Whole-cell extracts were prepared after cells were
trypsinized, collected and lysed by incubation with
Cell Lysis Buffer (#9803, Cell Signalling) on ice for 30 min
followed by centrifugation at maximum speed (15 000 rpm)
for 5 min at 4◦C. Chromatin-bound proteins were isolated
using a modification of protocol described by Mendez and
Stillman (42). A total of 3 × 106 cells were washed with
PBS, resuspended in 200 l of solution A (10 mM HEPES
at pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose,
10% glycerol, 1 mM dithiothreitol, 1 mM PMSF, phos-
phatase inhibitors [PhosStop, 04906837001 Roche] and
protease inhibitors [Complete Protease Inhibitor Cocktail,
Roche]) containing 0.1% Triton X-100, and incubated on
ice for 5 min. Cytoplasmic proteins were separated from
nuclei by low-speed centrifugation (1000 x g for 5 min at
4◦C). Isolated nuclei were washed once with solution A and
then lysed in 200 l of solution B (10 mM HEPES at pH
7.9, 3 mM EDTA, 0.2 mM EGTA, 1 mM dithiothreitol,
1 mM PMSF and protease and phosphatase inhibitors)
on ice for 30 min. Soluble nuclear proteins were separated
from insoluble chromatin by centrifugation (1500 x g for
5 min at 4◦C). Isolated chromatin was washed once with
solution B and centrifuged at 1500 x g for 5 min. The final
chromatin was resuspended in 200 l of buffer A without
glycerol and incubated with 100 U Benzonase Nuclease
(Novagen) to release chromatin bound proteins for 1 h
at room temperature. The samples were centrifugated at
maximum speed (15 000 rpm) for 5 min at 4◦C before
quantification by Bradford method (Bio-Rad). Twenty
microgram of protein from each sample were loaded.
Proteins were separated by SDS-PAGE and blotted
onto nitrocellulose (Whatman Schleicher & Schuell).
Primary antibodies used were: anti-H2AX (#2577),
anti-phosphoCHK1 Ser296 (#2349), anti-phosphoCHK1
Ser317 (#2344), anti-phosphoCHK1 Ser345 (#2348),
anti-CHK1 (#2360) from Cell Signaling; anti-H2AX
(ab11175), anti-RAD51 (ab213), anti-active caspase 3
(ab32042), anti-PP2CA (ab33537) from Abcam, anti-
RPA1 (sc-14696), anti-CDC45 (sc-20685) from Santa
Cruz Technology; anti-RPA2 (NA19L) from Calbiochem;
anti-PP4R2 (A300–838A), anti-phosphoRPA2 Ser33
(A300-246A), anti-phosphoRPA2 Ser-4,8 (A300-245A),
PALB2 (A301-246A) from Bethyl; or anti--actin (A-5060)
from Sigma. Proteins were detected using the enhanced
chemiluminiscence detection system (ECL, GE Health-
care) according to the manufacturer’s recommendations
and signals were recorded by means of LAS-3000 device
(Fujifilm). Image J software (http://rsbweb.nih.gov/ij/)
was used to process images and quantify protein band
intensities on the western blots.
In vitro lambda protein phosphatase treatment
Protein extracts were prepared after cells were collected
and lysed for 30 min incubation on ice in buffer 50 mM
Tris pH 7.5, 150 mM NaCl, 0.5% Igepal CA-630, 0.5 mM
PMSF and protease inhibitors. Protein samples were split
in two (500 g each), one of them was treated with 400
U/l lambda protein phosphatase (P0753, New England
BioLabs) plus 1 mM MnCl2 at 30◦C for 1 h, the other one
(negative control) was only incubated with MnCl2.
Detection of DSBs by pulsed-field gel electrophoresis
Cells were treated with 2 mM thymidine and/or Chk1 in-
hibitor Go¨6976 for 24 h. Following treatments, 106 cells
were embedded into agarose plugs. The agarose inserts were
incubated in 0.5 M EDTA pH 8.0, 0.2% sodium deoxy-
cholate, 1% N-laurylsarcosyl, and 1 mg/ml proteinase K at
50◦C for 24 h and then washed four times in TE buffer, be-
fore loading onto a 0.8% agarose gel. Pulsed-field gel elec-
trophoresis (120◦ angle, 60–240 s switch time, 4 V/cm; Bio-
Rad) was then carried out for 24 h. The gel was subse-
quently stained with ethidium bromide.
RESULTS
Nuclear RPA2 is extensively hyperphosphorylated in CHK1
inhibited cells treated with replication inhibitors
In addition to the recruitment of RPA to stalled replication
forks, RPA2 is heavily hyperphosphorylated in HCT116
cells after treatment with CHK1 and replication inhibitors
(37). To determine the extent of this hyperphosphoryla-
tion, chromatin-bound proteins from HCT116 cells treated
with the CHK1 inhibitor Go¨6976 (40) after treatment with
thymidine for various times were isolated and analysed
by western blotting. Notably chromatin-bound hyperphos-
phorylated RPA2 could be detected as early as 2 h after
treatment with the CHK1 inhibitor and thymidine (but not
by either agent alone) as indicated by the reduced elec-
trophoretic mobility of this protein (Figure 1A, Supple-
mentary Figure S1) and antibodies specific for phospho-
rylated forms of RPA2 (Figure 1B). By 16h nearly 70% of
chromatin-bound RPA2 was altered (Figure 1C). The sen-
sitivity of this slowly migrating RPA to  phosphatase treat-
ment confirmed that the altered mobility was the result of
phosphorylation (Figure 1D). Since immunofluorescence
analysis showed that 70% of cells contain pSer4,8 RPA2
foci (Figure 1E) our data suggest that the hyperphospho-
rylation of chromatin bound RPA2 under these conditions
is nearly complete. Like RPA2, increased loading of RPA1
onto chromatin was clearly evident by 2h however there was
no detectable change in the electrophoretic mobility of this
subunit (Figure 1F).
Similar levels of chromatin-bound hyperphosphorylated
RPA2were found inHCT116 cells treatedwith hydroxyurea
(HU) and CHK1 inhibitor (Supplementary Figure S2) and
in SW480 colon cancer cells treated with thymidine and the
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Figure 1. Nuclear RPA2 is extensively hyperphosphorylated in HCT116 cells treated with CHK1 inhibitor and thymidine. HCT116 cells treated or not
treated with the CHK1 inhibitor Go¨6976 in presence or absence of 2 mM thymidine were harvested at the indicated times and cytosolic, nuclear soluble or
chromatin bound fractions were isolated. RPA2 (A) or pSer4,8-RPA2 (B) in the chromatin fractions were then analysed by western blotting. Densitometric
measurements of phosphorylated RPA2 indicate that up to 70% of chromatin bound RPA2 is hyperphosphorylated (C). (D) Whole cell extracts obtained
from cells treated with thymidine for 24 h in the presence or absence of the CHK1 inhibitor in the right lanes of this blot were treated with -phosphatase to
confirm that the slowermigrating bandwas the result of phosphorylation ofRPA2.A blot of H2AX is presented as a control to confirm the effectiveness of
the phosphatase treatment. (E) Cultures of HCT116 cells treated for 24 h with Go¨6976 in presence or absence of 2mM thymidine were fixed and stained for
P-Ser4,8 RPA2 and the fraction of cells staining for this modified protein was determined by immunofluorescence. (F) Extracts prepared for panel A were
also analysed for RPA1 content. (G) Whole cell extracts prepared from HCT116 cells treated as above were probed with an antibody for pSer345CHK1.
Blots of all cellular fractions from this experiment are presented in Supplementary Figure S1. A western blot of those samples probed with an antibody
for the origin binding protein ORC2 is also presented in this figure as a control for the cellular fractionation and gel loading.
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CHK1 inhibitor (Supplementary Figure S3). The strong re-
cruitment of RPA1 and 2 to chromatin in the colon can-
cer cell lines treated with CHK1 and replication inhibitors
produced a noticeable decline in the cytosolic pools of these
proteins at>16h although they were not fully depleted. Nu-
clear soluble pools did not appear to be greatly affected
(Supplementary Figures S1–S3). Thus in contrast to previ-
ous studies using other tumour cell lines (36), our data sug-
gest that the pools of RPA1 and 2 are not exhausted in these
tumour cell lines by treatment with CHK1 and replication
inhibitors.
This early hyperphosphorylation of RPA2 was accompa-
nied by a robust phosphorylation of CHK1. ATR-mediated
phosphorylation of CHK1 at Ser345 and Ser317 follow-
ing DNA replication stress is essential for the activation of
its checkpoint functions. In the presence of the CHK1 in-
hibitor, this phosphorylation would be expected to continue
but the phosphorylated CHK1 would no longer be able to
fulfill its role in the downstream response to DNA replica-
tion stress. pSer345 and pSer317 CHK1markedly increased
in CHK1 inhibited cells within 2h of thymidine treatment
relative to cells treated with thymidine or CHK1 inhibitor
alone (Figure 1G, Supplementary Figure S4). In contrast
levels of autophosphorylated CHK1 (pSer296 CHK1) de-
creased in cells treated with the CHK1 inhibitor, indicating
the effectiveness of the CHK1 kinase inhibitor (43) (Sup-
plementary Figure S4). These data suggest that ATR (which
phosphorylates bothCHK1 andRPA2) is more strongly ac-
tivated in CHK1 inhibited tumour cells during replication
stress than in cells treated with a replication inhibitor alone,
consistent with the enhanced level of ssDNA found in such
cells (38,39).
Effects of CHK1 Inhibition on loading of replication and re-
pair proteins
Since the fate of cells treated with replication and CHK1 in-
hibitors is likely to be influenced by the response of DNA
repair and replication proteins, we next investigated the re-
cruitment of such proteins to chromatin under these con-
ditions. Given a report that RPA hyperphosphorylation
suppressed the loading of RAD51 onto ssDNA (33), the
levels of this protein bound to chromatin were first mea-
sured. Chromatin boundRAD51 increased inHCT116 cells
treated with thymidine by 16h (Figure 2A, Supplementary
Figure S5A). In contrast there was no change in chromatin
bound RAD51 in cells treated with Go¨6976 and thymidine,
where hyperphosphorylation of RPA2 was nearly complete.
It is also notable that the level of RAD51 in all cellular
fractions was appreciably lower in cells treated with the
CHK1 inhibitor, particularly in the presence of thymidine
(Supplementary Figure S5A). Thus the amount of RAD51
bound to chromatin was much lower in CHK1 inhibited
cells treatedwith thymidine whereRPA2was extensively hy-
perphosphorylated, however this decreased loading was ac-
companied by an overall decrease in the level of RAD51
in such cells (Supplementary Figure S2 and Figure 3A).
Similar effects on RAD51 loading were found in SW480
cells treated with thymidine and Go¨6976 however the over-
all level of RAD51 was not greatly reduced (Supplementary
Figure S3).
The PP4 phosphatase complex (including PP4 catalytic
and the PP4R2 regulatory subunits) has been shown to fa-
cilitate RAD51 binding to chromatin through its role in de-
phosphosphorylation of RPA2 (33). To determine whether
this complex also influenced RPA2 hyperphosphorylation
in CHK1 depleted cells, HCT116 cells were first analysed
for the recruitment of the PP4R2 subunit to chromatin fol-
lowing treatment with thymidine in the presence or absence
of Go¨6976. In the absence of the CHK1 inhibitor PP4R2
binding was elevated by 16 h post thymidine treatment rel-
ative to control cells (Figure 2B, Supplementary Figure
S5B). However, there was no corresponding increase in the
level of chromatin bound PP4R2 following treatment with
thymidine and theCHK1 inhibitor. Loading of PP4R2 onto
chromatin was also suppressed in SW480 cells treated with
thymidine andCHK1 inhibitor (Supplementary Figure S3).
In contrast binding of PP2A, which has been implicated in
the dephosphorylation of RPA2, H2AX and CHK1 (44–
46), was not altered in cells treated with thymidine in the
presence or absence of the CHK1 inhibitor (Supplementary
Figure S5C).
Given the role of CHK1 in controlling inappropriate ori-
gin firing during DNA replication stress and replication
fork integrity, we next investigated whether CHK1 inhibi-
tion also affected the localization of CDC45 which is an es-
sential helicase co-factor involved in replication initiation
in both yeast and human cells (47–49) and PALB2 which
has recently been shown to facilitate replication fork recov-
ery (35). Extracts prepared from cells treated as before with
Go¨6976 and/or thymidine were fractionated and analysed
for CDC45 and PALB2 (Figure 2C and D, Supplementary
Figure S5D). PALB2 was recruited to chromatin following
thymidine-induced replication stress in the presence or ab-
sence of the CHK1 inhibitor. In contrast chromatin bound
CDC45 increased in cells as early as 2 h after treatment with
thymidine and Go¨6976 consistent with the role of this pro-
tein in the increased firing of origins that occurs in the ab-
sence of CHK1 function. Thus, the loading of CDC45 onto
chromatin increased in cells under conditions where RPA2
is extensively hyperphosphorylated.
CDC45 depletion does not restore loading of PP4R2 or
RAD51 in CHK1 inhibited cells
We previously reported that when inappropriate origin fir-
ing in the absence of CHK1 was suppressed by CDC45 de-
pletion, both RPA2 hyperphosphorylation and the induc-
tion of caspase 3-dependent apoptosis were substantially re-
duced (37). To determine whether CDC45 depletion also re-
stored RAD51 or PP4R2 loading onto chromatin, HCT116
cells depleted of CDC45 were treated with thymidine in
the presence or absence of CHK1 inhibitor. We previously
showed that CDC45 depletion slowed S-phase progression
but had little effect on cell viability (37). Whole cell extracts
or chromatin bound fractions prepared from these cells
were analysed bywestern blotting. Consistent with previous
results, both RPA2 hyperphosphorylation and caspase 3 ac-
tivation were suppressed in CDC45 depleted cells treated
with thymidine and CHK1 inhibitor (Figure 3A and B). In
addition the elevated level of phosphorylated CHK1 found
in cells treated with the CHK1 inhibitor was reduced to
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Figure 2. Recruitment of DNA replication and repair proteins to chromatin in HCT116 cells in the presence or absence of CHK1 inhibitor and thymidine.
HCT116 cells treated or not treated with the CHK1 inhibitor Go¨6976 in presence or absence of 2 mM thymidine were harvested at the indicated times and
the chromatin bound fractions were analysed by western blotting. (A) RAD51, (B) PP4R2, (C) PALB2, (D) CDC45. Blots of all cellular fractions from
this experiment are presented in Supplementary Figure S5.
that found in cells treated with thymidine alone. Despite the
reduction of RPA2 hyperphosphorylation, neither RAD51
nor PP4R2 loading were restored (Figure 3B). Thus, RPA2
hyperphosphorylation alone is not responsible for the sup-
pression of RAD51 or PP4R2 loading in the absence of
CHK1 function.
Mutations of RPA2 phosphorylation sites fail to restore
RAD51 or PP4R2 loading
To further investigate the cellular effects of RPA2 hy-
perphosphorylation, we isolated HCT116 strains ectopi-
cally expressing wild type RPA2 (called RW, Figure 4A),
RPA2 mutated at CdK and ATR phosphorylation sites
(Ser33->Ala, Ser29->Ala and Ser23->Ala, called RM), or
RPA2 mutated at five serine residues contributing to hy-
perphosphorylation (Ser33->Ala, Ser29->Ala and Ser23-
>Ala, Ser8->Ala and Ser4->Ala, called R5M). To deter-
mine the effects of the constructs on cellular RPA2 con-
tent and phosphorylation, HCT116 and strains expressing
wild type or mutant RPA2 were transfected with control
siRNA or RPA2 siRNA targeted to the 3′ UTR of the en-
dogenous RPA2 transcript to deplete endogenous RPA2
but not the ectopically expressed protein (Figure 4B&C).
Cells were then treated with CHK1 inhibitor and/or thymi-
dine for 24h for preparation of whole cell and chromatin ex-
tracts for analysis of RPA2 by Western blotting. RPA2 and
RPA1 were substantially depleted and pSer4,8 RPA2 was
reduced in parental HCT116 cells following transfection
with the 3′ UTR siRNA (Figure 4B). In contrast the RW,
RM, and R5M derivatives retained a high level of RPA2
and RPA1 after transfection (Figure 4C and D). Hyper-
phosphorylatedRPA2 and pSer4,8RPA2were still detected
in RWwhile they were reduced in RM cells treated with the
RPA2 siRNA. However hyperphosphorylated RPA2 and
pSer4,8 RPA2 were not evident in whole cell or chromatin
extracts of R5M treated with CHK1 inhibitor, thymidine
and the RPA2 siRNA (Figure 4C and D).
To investigate the relationship between RAD51 and
PP4R2 loading and RPA2 hyperphosphorylation, chro-
matin isolated from the cells treated with thymidine in the
presence or absence of the CHK1 inhibitor was analysed for
RAD51 and PP4R2 content. Clearly RAD51 and PP4R2
loading onto chromatin were not regained in cells express-
ing the mutant RPA2 alleles where hyperphosphorylation
was suppressed following treatment with thymidine and the
CHK1 inhibitor (Figure 4D). Additionally RPA2 deple-
tion in HCT116 cells did not affect the loading of the two
proteins (Figure 4E). Thus, these data support our conclu-
sion that the failure to load RAD51 or PP4R2 in CHK1-
inhibited cells is not solely a consequence of RPA2 hyper-
phosphorylation or the level of chromatin bound RPA un-
der these conditions. It is also interesting to note that the re-
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Figure 3. CDC45 depletion suppresses RPA2 and CHK1 phosphorylation
and caspase 3 activation but fails to fully restoreRAD51 or PP4R2 binding
to chromatin. HCT116 cells transfected with control or CDC45 siRNAs
in the presence or absence of the CHK1 inhibitor Go¨6976 and/or 2 mM
thymidine were harvested after 24 for Western blot analysis. Whole cell
extracts (A) or chromatin bound proteins (B) from these cells were analysed
for the indicated proteins by Western blotting.
cruitment of PALB2 to chromatin inHCT116 cells occurred
in the presence or absence of RPA2 hyperphosphorylation.
Effects of mutant RPA2 on the fate of HCT116 cells treated
with CHK1 and replication inhibitors
Tumour cells treated with CHK1 and replication inhibitors
have been shown to suffer a number of fates including the in-
duction of apoptosis (1–3) and extensive induction of DSBs
(38). To determine whether RPA2 hyperphosphorylation
contributed to any of these outcomes, we next determined
the effects of expression of mutant and wild type RPA2
alleles. To investigate effects on the apoptotic response,
HCT116, RW, RM and R5M cells were treated with RPA2
3′ UTR siRNA to suppress the expression of the endoge-
nous wild type RPA2. After 48 h cells were harvested and
analysed for cell cycle distribution by flow cytometry. When
parental HCT116 was treated with RPA2 siRNA, cells ac-
cumulated in late S and G2/M consistent with the central
role played by RPA in DNA replication and many other
DNA transactions (Figure 5A). In contrast, as reported pre-
viously (29,30), the ectopically expressed wild type or mu-
tant RPA2 constructs were able to support the growth of
HCT116 cells after depletion of the endogenous wild type
RPA2 as RW, RM and R5M cells show a normal cell cycle
distribution (Figure 5A) with the exception of a significant
decrease in the level of cells with a subG1 DNA content in
the R5M cells (Figure 5A and C). Thus, both wild type and
mutant RPA2 are able to rescue cells transfected with RPA2
siRNA from S-G2/M arrest.
RW, RM, or R5M cells treated with the RPA2 3′ UTR
siRNA were then exposed to CHK1 inhibitors (Go¨6976 or
MK8776) in the presence or absence of thymidine for 48 h
before harvest and analysis of DNA content by flow cytom-
etry. Like HCT116, the fraction of RW cells with a subG1
content increased following co-treatment with CHK1 in-
hibitors and thymidine relative to cells treated with either
inhibitor alone (Figure 5B andC). In contrast the frequency
of similarly treated RM or R5M cells with a subG1 DNA
content was reduced. In parallel with the reduction of cells
with a subG1 content the fraction of S-phase cells increased
inRMandR5Mcultures treatedwithCHK1 inhibitors and
thymidine. The fractions of cells containing activated cas-
pase 3 were also measured in these experiments (Figure 5D
and E). Consistent with the reduction in the level of subG1
cells, the fractions of cells containing activated caspase 3
were reduced in both RM and R5M compared to RW af-
ter treatment with CHK1 inhibitors and thymidine.
RPA2 phosphorylation is not required to protect HCT116
cells from DSBs induced by CHK1 and replication inhibitors
Similarly some tumour cell lines show extensive DSB induc-
tion after treatment with CHK1 inhibitor as a single agent
or in combinationwith a replication inhibitor (38,50). How-
ever, the level of DSBs is low in HCT116 cells treated with
these inhibitors singly or in combination (37). To determine
whether expression of the mutant RPA2 affected the fre-
quency of DSBs, HCT116, RW, RM or R5M cells treated
the CHK1 inhibitor and/or thymidine were harvested and
analysed for DSBs by pulsed field gel electrophoresis (Fig-
ure 6). DSB formation increased in HCT116 cells depleted
of RPA2, again consistent with its role inDNAmetabolism.
The level of DSBs increased in RPA2-depleted cells treated
with Go¨6976 although the level of breaks was lower in
cells treated with both CHK1 and replication inhibitors. In
contrast expression of wild type or mutant RPA2 proteins
strongly reduced DSBs induced in HCT116 after siRNA-
mediated depletion of the endogenous RPA2 in the pres-
ence or absence of the inhibitors. Thus, the mutant RPA2
that lacks key phosphorylation sites is still able to protect
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Figure 4. Expression of a nonphosphorylatable RPA2 does not restore loading of RAD51 or PP4R2 onto chromatin after treatment with CHK1 and
replication inhibitors. (A) Mutant RPA2 cDNAs containing alterations of the indicated phosphorylation sites transfected into HCT116 cells used for
the isolation of strains stably expressing the mutant constructs. (B) Parental HCT116 cells transfected with control or RPA2 siRNAs (specific for the 3′
UTR of the endogenous RPA2 transcript) were treated or not treated with CHK1 inhibitor Go¨6976 in the presence or absence of 2mM thymidine. Cell
free extracts prepared from these cells were analysed for the indicated proteins by western blotting. (C) Protein extracts from parental cells and HCT116
cells ectopically expressing wild type or mutant RPA2 treated as in panel B were analysed by Western blotting for the indicated proteins. RPA2 levels
in RW and RM cells are about 50% greater than those in the HCT116 as determined by densitometry. The images presented here were over-exposed
to detect residual hyperphosphorylated RPA2. The 3′ UTR siRNA effectively depleted parental HCT116 cells of RPA2 but did not greatly affect the
overall level of RPA2 in RW or RM cells. Importantly hyperphosphorylated RPA2 was substantially reduced in the R5M cells (ectopically expressing the
nonphosphorylatablemutant RPA2) treated with thymidine and the CHK1 inhibitor. These cells also showed substantially reduced levels of pSer4,8-RPA2.
(D) Western blot analysis of indicated chromatin proteins prepared from parental HCT116 and strains ectopically expressing mutant and wild-type RPA2
as in Panel C. Notably the suppression of RPA2 hyperphosphorylation failed to restore RAD51 or PP4R2 binding to chromatin in HCT116 cells expressing
mutant RPA2. (E) Western blot analysis of indicated chromatin proteins prepared from parental HCT116 cells depleted or not depleted of RPA2. Notably
chromatin binding of RAD51 and PP4R2 are not affected by RPA2 depletion.
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Figure 5. Mutant RPA2 suppresses the accumulation of cells with a subG1 DNA content and caspase 3 activation after treatment with CHK1 and replica-
tion inhibitors. (A) Representative cell cycle profile for HCT116, RW, RM or R5M cells transfected with RPA2 siRNA, harvested after 72 h, and analysed
for DNA content by flow cytometry. (B) Representative profiles for HCT116, RW, RM and R5M cells transfected with RPA2 siRNA and treated with the
CHK1 inhibitors Go¨6976 (1 M) or MK8776 (1 M) in the presence or absence of 2 mM thymidine for 48 h before harvest and analysis of DNA content
by flow cytometry. (C) Summary of flow cytometry analyses as above. The data presented are the means of three independent experiments and error bars
represent standard deviations. The P values for the indicated measurements are relative to the results obtained for RW cultures treated in the same manner.
*P < 0.01; **P < 0.001; ***P < 0.0001. (D) The same cultures were analysed for caspase 3 activation by flow cytometry and the percentages of RW, RM
or R5M cells showing caspase 3 activation after these treatments are presented in (E). The data presented are the means of three independent experiments
and error bars represent standard deviations. The P values for the indicated measurements are relative to the results obtained for RW cultures treated in
the same manner. *P < 0.01; **P < 0.001; ***P < 0.0001.
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Figure 6. DSB analysis of HCT116 and strains expressing wild type and
mutant RPA2. Parental HCT116 and strains ectopically expressing wild
type or mutant RPA2 were depleted of endogenous RPA2 by transfec-
tion of the 3′ UTR siRNA before a 24 h treatment with 1 M Go¨6976
and 2 mM thymidine. Cells were then harvested for analysis of DSBs by
pulsed field gel electrophoresis. RPA2 depletion triggers DSB formation in
HCT116 but this is rescued by ectopic expression of mutant or wild type
RPA2. Neither thymidine nor CHK1 inhibitors alone or in combination
enhance DSB formation in RPA2 depleted cells ectopic expression of mu-
tant RPA2s is still able to rescue HCT116 from DSB formation.
HCT116 cells fromDSBs induced by RPA2 depletion or by
CHK1 and replication inhibitors.
DISCUSSION
When DNA synthesis is arrested proteins required for re-
pair of blocking lesions and replication restart are recruited
to stalled forks and there is compelling evidence that the
ATR-CHK1 signalling pathway plays a key role in coordi-
nating this response (51). In the absence of ATR-CHK1 sig-
nalling these responses are disrupted, potentially leading to
a loss of replication fork integrity and cell death. Consistent
withmany previous studies we show that one of the key pro-
teins recruited to DNA when DNA replication is arrested,
RPA2, is extensively hyperphosphorylated following treat-
ment with DNA replication and CHK1 inhibitors. Hyper-
phosphorylation commences early after induction of repli-
cation stress and is accompanied by increased phosphoryla-
tion of H2AX (52). RPA2 phosphorylation occurs at stalled
replication forks (53) and suppresses the loading of other
proteins (such as RAD51) essential for replication restart
(33,54). Consequently RPA2 phosphorylation is normally
carefully controlled, in part by protein phosphatase com-
plexes that are also recruited to DNA upon replication ar-
rest (33). Here we show that the loading of RAD51 together
with a component of the PP4 protein phosphatase complex
(PP4R2) are suppressed by CHK1 inhibition and the failure
to activate these repair pathways is likely to underlie the in-
ability of cells treated with replication and CHK1 inhibitors
to reenter and complete S-phase after release (52). However
our data suggest that hyperphosphorylation of RPA2 is not
directly responsible for the failure to load these proteins as
suppression of this phosphorylation by CDC45 depletion
Figure 7. Model for the induction of apoptosis in cells lackingCHK1 func-
tion during replication stress. In normal cells DNA replication fork stress
generates ssDNAas a result of uncoupling of replication and helicase com-
plexes. RPA coated ssDNA triggers activation of the ATR-CHK1 pathway
to enhance survival by suppressing origin firing and apoptosis and stim-
ulating S-phase checkpoints and HR-dependent replication fork restart.
Our results indicate that CHK1 is also required for the loading of the PP4
protein phosphatase complex onto chromatin to control phosphorylation
of RPA2.When CHK1 is inhibited or depleted, cells fail to trigger S-phase
checkpoints or fork restart and fail to load the PP4 complex onto chro-
matin. Cells lose control of CDC45-dependent origin firing leading to the
accumulation of RPA-coated ssDNA and enhanced activation of ATR.
This together with the failure to load the PP4 protein phosphatase com-
plex and activation of DNA-PK leads to extensive hyperphosphorylation
of RPA2. Depletion of CDC45 substantially reduces ssDNA formation,
RPA2 hyperphosphorylation, ATR activation, and apoptosis while sup-
pression of RPA2 hyperphosphorylation alone reduces the level of apop-
tosis. While these data are consistent with the proposal that ssDNA for-
mation driven by inappropriate firing of replication origins in the absence
of CHK1 function commit cells to apoptosis through RPA2 hyperphos-
phorylation, it is also likely that other cellular responses to the high level
of ssDNA may also contribute to the induction of apoptosis.
or by mutation of RPA2 phosphorylation sites failed to re-
store RAD51 or PP4R2 loading. Thus, these observations
suggest that CHK1 itself is the primary mediator of these
protective pathways. A previous report that CHK1 affects
RAD51 function through post-translational phosphoryla-
tion (19) supports this conclusion. Post-translational phos-
phorylation sites for PP4R2 have been identified although it
is not known how these respond to DNA replication stress
in the presence or absence of CHK1.
While our data appear to conflict with some previous
work, a major difference in our study is the effect of CHK1
inhibition which greatly enhances the level of stress in cells
exposed to replication inhibitors. Inappropriate firing of
replication origins during DNA replication stress in the ab-
sence of a functional ATR-CHK1 signalling cascade sub-
stantially increases the level of ssDNA and RPA binding
relative to that found during replication stress in cells con-
taining active CHK1 (18,37) (Figure 7). Our evidence sug-
gests that this in turn amplifies ATR signaling (which is de-
pendent upon RPA coated ssDNA (12)) and consequently
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the level of phosphorylated RPA2. Previous work shows
that the phosphorylation of Ser33 by ATR is critical for the
‘sequential and synergistic’ phosphorylation at other sites
(29). Consistent with this, DNA-PK activity is also acti-
vated in the absence of CHK1 (55) facilitating the phos-
phorylation of ‘downstream’ RPA2 phosphorylation sites.
Since the loading of the PP4 phosphatase complex onto
chromatin is dependent upon CHK1, another important
restraint of RPA2 phosphorylation is lost when CHK1 is
inhibited (Figure 7). As a result, hyperphosphorylation of
RPA2 is amplified in the absence of CHK1 function.
Another characteristic of cells treated with CHK1 and
replication inhibitors is their commitment to apoptosis.
This is a late event and dependent upon CDC45 (37).
CDC45 is an essential helicase cofactor that participates in
both the initiation and elongation steps of DNA synthe-
sis (47,49,56). Its depletion suppresses ssDNA formation,
recruitment and hyperphosphorylation of RPA, and cell
death (37). The data presented here show that widespread
hyperphosphorylation of RPA2 promotes the induction of
cell death as the substitution of RPA2 with a protein lack-
ing several phosphorylation sites reduced the level of apop-
totic cells as measured by subG1DNA content and caspase
3 activation. Thus we propose that the substantial reduc-
tion of cell death by CDC45 depletion reflects an early role
in the pathway of events that lead to apoptosis in the ab-
sence of CHK1 functionwhileRPA2 hyperphosphorylation
is a later, downstream event. This suggests that extensive ss-
DNA formation under these conditions may be the primary
determinant of cell fate (Figure 7).
A number of reports show that cell death following in-
hibition of the ATR-CHK1 signalling cascade is linked to
DSB formation at stalled replication forks (36,38,50). Re-
cently this has been attributed to an exhaustion of RPA
pools in cells treated with an ATR inhibitor making ss-
DNA at stalled forks vulnerable to attack by structure-
specific endonucleases, a response called ‘replicative catas-
trophe’(36). This does not appear to be the case forHCT116
following treatment with CHK1 and replication inhibitors
as pools of RPA1 and RPA2 do not appear to be exhausted
in these cells and there is little DSB formation. Here we
tested the possibility that RPA2 hyperphosphorylation pro-
tected stalled forks in HCT116 from collapse. However mu-
tant RPA2 lacking hyperphosphorylation was as effective
as wild type RPA2 in rescuing cells from DSB formation.
Given our findings that RPA2 hyperphosphorylation is
extensive in tumour cells treated with CHK1 andDNA syn-
thesis inhibitors and that this response promotes the cellu-
lar commitment to apoptosis, we propose that RPA2 hy-
perphosphorylation might prove useful as a biomarker to
predict the efficacy of therapies including CHK1 inhibitors.
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